G-protein-coupled Receptor Kinase Specificity for Beta-arrestin Recruitment to the Beta2-adrenergic Receptor Revealed by Fluorescence Resonance Energy Transfer
Overview
Affiliations
The small family of G-protein-coupled receptor kinases (GRKs) regulate cell signaling by phosphorylating heptahelical receptors, thereby promoting receptor interaction with beta-arrestins. This switches a receptor from G-protein activation to G-protein desensitization, receptor internalization, and beta-arrestin-dependent signal activation. However, the specificity of GRKs for recruiting beta-arrestins to specific receptors has not been elucidated. Here we use the beta(2)-adrenergic receptor (beta(2)AR), the archetypal nonvisual heptahelical receptor, as a model to test functional GRK specificity. We monitor endogenous GRK activity with a fluorescence resonance energy transfer assay in live cells by measuring kinetics of the interaction between the beta(2)AR and beta-arrestins. We show that beta(2)AR phosphorylation is required for high affinity beta-arrestin binding, and we use small interfering RNA silencing to show that HEK-293 and U2-OS cells use different subsets of their expressed GRKs to promote beta-arrestin recruitment, with significant GRK redundancy evident in both cell types. Surprisingly, the GRK specificity for beta-arrestin recruitment does not correlate with that for bulk receptor phosphorylation, indicating that beta-arrestin recruitment is specific for a subset of receptor phosphorylations on specific sites. Moreover, multiple members of the GRK family are able to phosphorylate the beta(2)AR and induce beta-arrestin recruitment, with their relative contributions largely determined by their relative expression levels. Because GRK isoforms vary in their regulation, this partially redundant system ensures beta-arrestin recruitment while providing the opportunity for tissue-specific regulation of the rate of beta-arrestin recruitment.
Cannabinoid Tolerance in S426A/S430A x -Arrestin 2 Knockout Double-Mutant Mice.
Piscura M, Sepulveda D, Maulik M, Guindon J, Henderson-Redmond A, Morgan D J Pharmacol Exp Ther. 2023; 385(1):17-34.
PMID: 36669876 PMC: 10029824. DOI: 10.1124/jpet.122.001367.
Glaser K, Tarrant T, Lammermann T Front Immunol. 2022; 13:1039803.
PMID: 36451830 PMC: 9703078. DOI: 10.3389/fimmu.2022.1039803.
Dual fluorescent labeling of GLP-1R in live cells enzymatic tagging and bioorthogonal chemistry.
Lewandowski T, An P, Ramil C, Fang M, Lin Q RSC Chem Biol. 2022; 3(6):702-706.
PMID: 35755189 PMC: 9175107. DOI: 10.1039/d2cb00107a.
Double life: How GRK2 and β-arrestin signaling participate in diseases.
Zhai R, Snyder J, Montgomery S, Sato P Cell Signal. 2022; 94:110333.
PMID: 35430346 PMC: 9929935. DOI: 10.1016/j.cellsig.2022.110333.
Discovery of a functionally selective ghrelin receptor (GHSR) ligand for modulating brain dopamine.
Gross J, Kim D, Zhou Y, Jansen D, Slosky L, Clark N Proc Natl Acad Sci U S A. 2022; 119(10):e2112397119.
PMID: 35239443 PMC: 8915830. DOI: 10.1073/pnas.2112397119.